The association between naltrexone compliance and daily supervision

Drug and Alcohol Review

Volumn 19, Issue 1, 2000, Pages 41-48

  Hulse, G K ^a,b   Basso, M R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Alcohol and Drug Educ and Train ^*

Author keywords

Medicine compliance; Naltrexone maintenance; Supervision; Treatment retention

Indexed keywords

EID: 0034395939     PISSN: 09595236     EISSN: None     Source Type: Journal    
DOI: 10.1080/09595230096138     Document Type: Article

References (19)

1. Julius D. NIDA's naltrexone research program. In: Julius D, Renault P, eds. Narcotic antagonists: naltrexone, NIDA research monograph no 9. Rockville, MD: National Institute of Drug Abuse, 1976:5-11.
2. National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Arch Gen Psychiatry 1978;35:335-40.
3. Tennant FS, Rawson RA, Cohen AJ, Mann A. Clinical experience with naltrexone in suburban opioid addicts. J Clin Psychiatry 1984;45:42-5.
4. San L, Pomarol G, Peri JM, Olle JM, Cami J. Follow-up after six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 1991;86:983-90.
5. Anton RE, Hogan I, Jalali B, Riordan CE, Kleber HD. Multiple family therapy and naltrexone in the treatment of opiate-dependence. Drug Alcohol Depend 1981;8:157-68.
6. Bell JR, Young MR, Masterman SC, Morris A, Mattick RP, Bammer G. A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust 1999:171:26-30.
7. Callahan EJ, Rawson RA, McCleave B. The treatment of heroin addiction: naltrexone alone and with behaviour therapy. Int J Addict 1980:15;795-807.
8. Chan KY. The Singapore naltrexone community-based project for heroin addicts compared with drugfree community-based program: the first cohort. J Clin Forensic Med 1996;3:87-92.
9. Garcia-Alonso F, Gutierraz M, San L, et al. A multicentre study to introduce naltrexone for opiate-dependence in Spain. Drug Alcohol Depend 1989;23:117-21.
10. Freedman RR, Czertko G. A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts. Drug Alcohol Depend 1981;8: 215-22.
11. Ball JC, Ross A, eds. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome. New York: Springer-Verlag, 1991.
12. Havassy B, Hall S. Efficacy of urine monitoring in methadone maintenance. Am J Psychiatry 1981;99: 1497-500.
13. Schwartz B, Layderdale RM, Montgomery ML, Burch EA, Gallant DD. Immediate versus delayed feedback on urinalysis reports for methadone maintenance patients. Addict Behav 1987;12:293-5.
14. Thomas M, Kaunders F, Harris M, Cooperstein J, Hough G, Resnick R. Clinical experiences with naltrexone in 370 detoxified addicts. In: Julius D, Renault P, eds. Narcotic antagonists: naltrexone, NIDA research monograph no. 9. Rockville, MD: National Institute of Drug Abuse, 1976: 88-92.
15. Azrin NH, Sisson RW, Meyers R, Godley M. Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatr 1982;13:105-12.
16. Lerner AG, Sigal M, Gelkopf M. Naltrexone abuse and risk of suicide. J Nerv Ment Dis 1993:181:706-7.
17. Miotto K, McCann MJ, Rawson RA, et al. Overdose, suicide attempts and death among a cohort of naltrexone-treated opiod addicts. Drug Alcohol Depend 1997;45:131-4.
18. Swensen G. Monograph: 1998 overview of opioid related deaths in WA Jan-August 1997. Western Australia: WA Drug Abuse Strategy Office, 1998.
19. Western Australia Taskforce on Drug Abuse. Protecting the community, report of the Taskforce on Drug Abuse. Perth, WA: Frank Daniels Pty Ltd, 1995.